Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

No dose adjustments occurred during the observation period, and no significant adverse events were reported (e.g., hypersensitivity reactions, hyperphosphatemia, kidney stones).Patients’ baseline characteristicsVariablesXLH (n = 27)GeneralAge (years)42 ± 13Female sex, n (%)13 (48)Weight (Kg)60 (55 to 78)Height (cm)150 (144 to 155)BMI (kg/m2)27 (25 to 32)XLH-related clinical dataPHEX mutation, n (%)23 (85)Family history of rickets, n (%)8 (30)Lower limb deformities and/or previous orthopedic surgery, n (%)25 (93)Fragility fractures/pseudofractures, n (%)19 (70)Enthesopathies, n (%)16 (59)Nephrolithiasis, n (%)9 (33)Dental abnormalities, n (%)16 (59)Laboratory testsSerum phosphate (mg/dL)1.5 (1.3 to 1.8)TmP/GFR (mg/dL)1.3 (0.9 to 1.5)Serum calcium (mg/dL)9.4 (9.0 to 9.6)Urinary calcium (mg/24 h)119 (82 to 148)25-OH-vitamin D (nmol/L)64 (49 to 89)Serum creatinine (mg/dL)0.65 (0.57 to 0.74)eGFR (ml/min/1.73 m2)115 (109 to 126)Data presented as mean ± SD or median and interquartile rangeBMI = body mass index, eGFR = estimated glomerular filtration rate, PHEX = phosphate regulating endopeptidase X-linked, TmP/GFR = tubular maximum phosphate reabsorption per glomerular filtration rate, XLH = X-linked hypophosphatemia

Source: Patients’ characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

None of the enrolled patients were members of the same family (i.e.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Predictors of response to burosumab in adults with X-linked hypophosphatemia: real-world data from an Italian cohort

Study design awaiting verification · Journal of Endocrinological Investigation · 2025

Original publication title

Predictors of response to burosumab in adults with X-linked hypophosphatemia: real-world data from an Italian cohort

Gaetano Paride Arcidiacono; Valentina Camozzi; Giovanni Tripepi; Cristina Eller-Vainicher; Giuseppe Vezzoli; Maria Luisa Brandi; Gemma Marcucci; Giuseppe Girasole; Antonio Aversa; Corrado Vitale; Gaetana Cerbone; Maria Michela D’Alessandro; Martina Zaninotto; Maria Fusaro; Marco Onofrio Torres; Michele Cannito; Alberta Cecchinato; Martin Diogo; Mor Peleg Falb; Francesca Guidolin; Marta Zampogna; Mario Plebani; Elena Campello; Paolo Simioni; Stefania Sella; Sandro Giannini

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Burosumab effectively increased serum phosphate levels and improved clinical outcomes in a real-world setting, particularly in patients with more substantial increases in serum phosphate levels. Baseline serum phosphate, PTH, and FGF23 levels predicted response, helping tailor treatment strategies and improve long-term patient management.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

X-linked hypophosphatemia (XLH) is a genetic disorder characterized by elevated FGF23 levels, leading to phosphate wasting and hypophosphatemia, causing skeletal and extraskeletal abnormalities. Burosumab, an antibody targeting FGF23, improves hypophosphatemia and clinical outcomes. This study evaluated the real-world efficacy of burosumab and identify predictors of treatment response.

Source: Purpose

Abstract: What methods does the paper describe?

Twenty-seven adult XLH patients (mean age 42 years; 48% female) from an Italian multicenter cohort were treated with burosumab for up to 24 weeks. Laboratory tests were evaluated at midpoints and endpoints (14 and 28 days) of the dosing interval. In a subset of patients (N = 11) followed for 48 weeks, laboratory tests and patient-reported outcomes were also assessed.

Source: Methods

Abstract: Results

After initiating burosumab, median serum phosphate levels increased from 1.5 mg/dL (IQR 1.3 to 1.8) to 2.0 mg/dL (IQR 1.7 to 2.4) (p < 0.05), remaining higher than baseline at the midpoints of the dosing interval for up to 24 weeks. Higher baseline phosphate predicted higher midpoint levels (p < 0.05), whereas higher baseline PTH (p < 0.05) and FGF23 (p < 0.001) were associated with lower phosphate levels at midpoints. In patients (N = 11) followed for 48 weeks, significant improvements in patient-reported outcomes in all patients were observed.

Both WOMAC Pain (r = 0.94, p = 0.02) and BPI Worst Pain (r = 0.98, p < 0.001) were positively correlated with increased phosphate at week 48.

Source: Results

Abstract: Conclusion

Burosumab effectively increased serum phosphate levels and improved clinical outcomes in a real-world setting, particularly in patients with more substantial increases in serum phosphate levels. Baseline serum phosphate, PTH, and FGF23 levels predicted response, helping tailor treatment strategies and improve long-term patient management.

Source: Conclusion
Authors’ abstract

Purpose

X-linked hypophosphatemia (XLH) is a genetic disorder characterized by elevated FGF23 levels, leading to phosphate wasting and hypophosphatemia, causing skeletal and extraskeletal abnormalities. Burosumab, an antibody targeting FGF23, improves hypophosphatemia and clinical outcomes. This study evaluated the real-world efficacy of burosumab and identify predictors of treatment response.

Methods

Twenty-seven adult XLH patients (mean age 42 years; 48% female) from an Italian multicenter cohort were treated with burosumab for up to 24 weeks. Laboratory tests were evaluated at midpoints and endpoints (14 and 28 days) of the dosing interval. In a subset of patients (N = 11) followed for 48 weeks, laboratory tests and patient-reported outcomes were also assessed.

Results

After initiating burosumab, median serum phosphate levels increased from 1.5 mg/dL (IQR 1.3 to 1.8) to 2.0 mg/dL (IQR 1.7 to 2.4) (p < 0.05), remaining higher than baseline at the midpoints of the dosing interval for up to 24 weeks. Higher baseline phosphate predicted higher midpoint levels (p < 0.05), whereas higher baseline PTH (p < 0.05) and FGF23 (p < 0.001) were associated with lower phosphate levels at midpoints. In patients (N = 11) followed for 48 weeks, significant improvements in patient-reported outcomes in all patients were observed.

Both WOMAC Pain (r = 0.94, p = 0.02) and BPI Worst Pain (r = 0.98, p < 0.001) were positively correlated with increased phosphate at week 48.

Conclusion

Burosumab effectively increased serum phosphate levels and improved clinical outcomes in a real-world setting, particularly in patients with more substantial increases in serum phosphate levels. Baseline serum phosphate, PTH, and FGF23 levels predicted response, helping tailor treatment strategies and improve long-term patient management.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40618-025-02596-3.

Publication and source details

Original title: Predictors of response to burosumab in adults with X-linked hypophosphatemia: real-world data from an Italian cohort

Gaetano Paride Arcidiacono; Valentina Camozzi; Giovanni Tripepi; Cristina Eller-Vainicher; Giuseppe Vezzoli; Maria Luisa Brandi; Gemma Marcucci; Giuseppe Girasole; Antonio Aversa; Corrado Vitale; Gaetana Cerbone; Maria Michela D’Alessandro; Martina Zaninotto; Maria Fusaro; Marco Onofrio Torres; Michele Cannito; Alberta Cecchinato; Martin Diogo; Mor Peleg Falb; Francesca Guidolin; Marta Zampogna; Mario Plebani; Elena Campello; Paolo Simioni; Stefania Sella; Sandro Giannini

Journal of Endocrinological Investigation · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Università degli Studi di Padova

Open access funding provided by Università degli Studi di Padova within the CRUI-CARE Agreement.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T05:22:44.689305+00:00

DOI: 10.1007/s40618-025-02596-3 · PMC12313718